Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Arrowhead Pharmaceuticals Inc.
Sponsor

Arrowhead Pharmaceuticals Inc.

United States 177 East Colorado Boulevard Suite 700, 91105-1976, United States

About the sponsor

Arrowhead Pharmaceuticals Inc. is active in clinical research for hypertriglyceridemia, severe hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia syndrome, with a strong emphasis on therapies aimed at lowering circulating triglycerides and addressing acute pancreatitis risk.

  • Hypertriglyceridemia and severe hypertriglyceridemia
  • Familial chylomicronemia syndrome
  • Mixed dyslipidemia
  • Acute pancreatitis prevention

The sponsor also studies apolipoprotein C-III-directed and related lipid-lowering approaches in adults with inherited and multifactorial lipid metabolism disorders.

About Specializations

Arrowhead Pharmaceuticals Inc. runs clinical trials in conditions such as Hypertriglyceridaemia, Type IIa hyperlipidaemia, Asthma, Chronic obstructive pulmonary disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

12 clinical trials

Type IIa hyperlipidaemia

Recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:ZODASIRAN
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Type IIa hyperlipidaemia

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ZODASIRAN
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Asthma+1

Not recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ads-013
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Familial hypertriglyceridaemia

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Type V hyperlipidaemia

Not recruiting
InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Asthma

Not recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ads-015
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Immune-mediated renal disorder

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ads-011
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.